CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma - Sun, Yichen; Gao, Yan; Chen, Jianfeng; Huang, Ling; Deng, Peng; Chen, Jinghong; Chai, Kelila Xin Ye; Hong, Jing Han; Chan, Jason Yongsheng; He, Haixia; Wang, Yali; Cheah, Daryl; et al. (Cancer letters, 2021)
Keywords: Antitumor activity; B-cell lymphoma; Biomarkers; Cancer therapies; Cell cycle; Cell growth; Chidamide; Clinical trials; CREBBP; DLBCL; Drug screening; Epigenetics; Experiments; Histone acetyltransferase; Histone deacetylase; Lymphocytes B; Lymphoma; Mutation; Patients; Plasmids; Resistance; Software; Resistance; DLBCL; CREBBP; Chidamide; Cell cycle